Log In Get Started
Insider Trading January 22, 2026

Guardant Health's Chief People Officer Divests Nearly $1 Million in Shares Amid FDA Milestone and Analyst Upgrades

Terilyn J. Monroe reduces her stake following a series of strong corporate developments and analyst optimism

By Jordan Park GH
Guardant Health's Chief People Officer Divests Nearly $1 Million in Shares Amid FDA Milestone and Analyst Upgrades
GH

Terilyn J. Monroe, Chief People Officer of Guardant Health, divested 8,571 shares valued at approximately $977,900 on January 21, 2026, amid a backdrop of encouraging FDA approval and positive analyst sentiment. The transactions occurred at prices ranging from $112.34 to $115.70 per share. Guardant Health has recently achieved FDA clearance for its Guardant360 CDx test as a companion diagnostic for a specific colorectal cancer mutation, which was bolstered by clinical trial successes. Market analysts have accordingly raised their price targets for the company, highlighting its promising growth trajectory and upcoming catalysts.

Key Points

  • Terilyn J. Monroe, Guardant Health's Chief People Officer, sold 8,571 shares valued near $977,900 at prices between $112.34 and $115.70 per share.
  • Guardant Health obtained FDA approval for its Guardant360 CDx companion diagnostic targeting BRAF V600E-mutant metastatic colorectal cancer, supported by Pfizer's successful Phase 3 BREAKWATER trial results.
  • Multiple investment banks, including Stifel, Jefferies, and BTIG, have raised price targets and ratings on Guardant Health, signifying positive market outlooks amid ongoing product developments and upcoming catalysts.

On January 21, 2026, Terilyn J. Monroe, Guardant Health, Inc.'s Chief People Officer, executed the sale of 8,571 shares of the company's common stock, as detailed in a recent Form 4 filing submitted to the U.S. Securities and Exchange Commission. The disposition generated proceeds of approximately $977,901, with executed share prices fluctuating between $112.34 and $115.70 across multiple transactions.

A breakdown of the trades reveals that Monroe sold 1,703 shares at an average price of $112.34 per share, 3,619 shares averaging $113.48, and an additional 3,249 shares at an average price of $115.70. Subsequent to these sales, Monroe retains ownership of 20,990 Guardant Health shares.

Concurrently, Guardant Health has secured Food and Drug Administration approval for its Guardant360 CDx assay, designating it as a companion diagnostic to detect BRAF V600E-mutant metastatic colorectal cancer patients. This milestone was underpinned by robust clinical data derived from Pfizer's Phase 3 BREAKWATER study, which demonstrated meaningful clinical benefits using a regimen of encorafenib and cetuximab coupled with chemotherapy.

Reflecting these favorable developments, investment banking firms Stifel and Jefferies have upgraded their price targets on Guardant Health's shares to $120 and $130 respectively, while affirming Buy ratings. These updates incorporate expectations of sustained growth and significant upcoming catalysts. Furthermore, BTIG has identified Guardant Health as one of its leading recommendations for 2026, citing the company's potential driven by products such as Shield CRC and Shield MCED.

In addition to U.S.-based advancements, Guardant Health's technological footprint has expanded internationally. In Italy, the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has inaugurated an on-site liquid biopsy testing facility utilizing Guardant Health's platform, enhancing local cancer diagnostic capabilities by enabling comprehensive genomic profiling without the logistical delays of sending samples abroad.

Risks

  • The insider stock sale could be perceived by some investors as a reduction in executive optimism, possibly affecting market sentiment.
  • Approval and integration of new diagnostics like Guardant360 CDx depend on successful clinical validation and regulatory compliance, which may encounter unforeseen challenges.
  • Though analyst upgrades signal promise, market expectations might not materialize as anticipated, and international expansions, such as the Italian facility, may involve operational risks impacting future performance.

More from Insider Trading

Symbotic Accounting Chief Disposes $457,722 in Shares as Company Prices 10M-Share Offering; Goldman Lowers Rating Feb 2, 2026 Wintrust Financial EVP Sells 5,000 Shares as Firm Announces Dividend Hike and Multiple Price-Target Upgrades Jan 30, 2026 Cantor Fitzgerald Affiliates Dispose of Satellogic Shares in $2.94M Transaction Block Jan 30, 2026 Navan Interim CFO Executes $37,044 Sell-to-Cover Transaction Jan 30, 2026 Bluescape entity disposes of $4.2M in Riley Exploration stock amid company asset sale and capital actions Jan 30, 2026